Dupixent — Medica
Chronic Rhinosinusitis with Nasal Polyps
Initial criteria
- age ≥ 12 years
- diagnosis confirmed by direct examination, endoscopy, or sinus CT scan
- two or more symptoms (nasal congestion, nasal obstruction, nasal discharge, or reduction/loss of smell) for at least 6 months
- received at least 4 weeks of intranasal corticosteroid therapy
- will continue intranasal corticosteroid with Dupixent
- meets one of the following: received ≥ 1 course of systemic corticosteroid within previous 2 years OR contraindication to systemic corticosteroid therapy OR prior nasal polyp surgery
- prescribed by or in consultation with allergist, immunologist, or otolaryngologist (ENT)
Reauthorization criteria
- already received ≥ 6 months of Dupixent therapy
- continues use of intranasal corticosteroid
- has responded to therapy as determined by prescriber (e.g., reduced nasal polyp size, improved nasal congestion, reduced sinus opacification, decreased sinonasal symptoms, improved sense of smell)
Approval duration
initial 6 months, renewal 1 year